glp-1 and ibd Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, therapeutic potential Relevance of Glucagon-Like Peptide 1

This approval expands the potential patient base and strengthens Novo Nordisks position against rival Eli Lilly, as demand grows for effective obesity treatments amid rising healthcare costs

Andreadis P, Karagiannis T, Malandris K, Avgerinos I, Liakos A, Manolopoulos A, et al

Interesting data focused on GLP1 RA Reassuring data, however mostly just lean body mass not specifically muscle was measured We still need more data on more frail population To view or add a comment, sign in More Relevant Posts One of the most interesting obesity drug stories right now is not about losing weight

[00:15:29] Emily Field: It tells the body this tissue is still needed

The braingut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study